Hainan Hailing Chemipharma · Corporate Film
Hailing Pharma Film: Captions, Transcript & Chapters
Chinese and English captions, complete transcript, chapter summaries, duration, web publication date and historical-content notice for the archival Hailing Pharma corporate film.
Download captions
English VTT中文 VTTChapter summary
- Health and a commitment to lifelong careAn opening reflection on health, family responsibility and lifelong care.
- Origins and corporate developmentThe film recounts Hailing Pharma's founding and its historical corporate development.
- Manufacturing portfolio and quality systemHistorical manufacturing, dosage-form and quality-management statements shown in the film.
- Research, development and innovation networkThe film introduces R&D investment, talent, external collaboration and historical innovation progress.
- Commercial network and historical market positionHistorical sales-network and market-position statements presented by the original film.
- Service, reputation and historical recognitionThe film describes service values, reputation and recognitions associated with its production period.
- Facilities, exports and international visionA closing account of historical facility plans, export ambitions and the company's international outlook.
Complete transcript
0:00–0:23
Health and a commitment to lifelong care
An opening reflection on health, family responsibility and lifelong care.
Everyone lives only once ... and is entitled to have a splendid life. A healthy life is not only a duty or a lifestyle attitude, but is also a commitment made to loved ones. For the commitment to your health, we pledge ourselves to provide lifelong care.
0:23–1:15
Origins and corporate development
The film recounts Hailing Pharma's founding and its historical corporate development.
Founded in 2004, Hailing Pharma has always been committed to the development, production, and distribution of high-quality, safe, and effective pharmaceutical products. Currently, it owns a number of subsidiaries in Hainan, Shanghai, Hong Kong, Hunan, and Tibet, etc. In January 2016, Hailing Pharma became a holding subsidiary of Changjiang Runfa Group, which is one of top 500 private companies in China, and its total assets exceeded 3.8 billion RMB. On November 18, 2016, Hailing Pharma became a publicly listed company on the Shenzhen Stock Exchange. Hailing Pharma now serves as the flagship company under Changjiang Runfa's ambitious strategic plan in the healthcare industry.
1:15–2:37
Manufacturing portfolio and quality system
Historical manufacturing, dosage-form and quality-management statements shown in the film.
It is a high-tech enterprise with four modern manufacturing plants of raw materials and preparations, and all manufacturing plants have already passed the China GMP certification. It has over 130 different pharmaceutical products and certificates, such as powder injection, freeze-dried powder injection, small volume injection, tablets, capsules, granules, and others, including anti-infective drugs, cardiovascular drugs, digestive system drugs, nervous system drugs, diabetes, and dermatologic products, etc. In order to pursue top quality, Hailing Pharma started to adopt the U.S. cGMP, current Good Manufacturing Practice Standards, and implemented a world-class quality management system, QMS. The new QMS covers every aspect of its operations, such as product development, raw material inspection, production process, quality control, warehouse management, logistics, and customer service. Hailing Pharma staff scrutinize every detail during the production. With this world-class quality standard, Hailing Pharma ensures all the pharmaceutical products enter the market with high brand reputation and provide the health protection to all the people.
2:37–3:28
Research, development and innovation network
The film introduces R&D investment, talent, external collaboration and historical innovation progress.
Hailing Pharma dedicated significant resources to new pharmaceutical product research and development and recruited leading talent and experts to build innovation technology platform. The company has also built an extensive partnership with distinguished R&D institutions, universities, and pharmaceutical manufacturers in domestic China, America, Japan, Canada, and India, etc. Building on continuous learning of cutting-edge technology, Hailing Pharma's R&D team keeps developing innovative pharmaceutical products with proprietary intellectual property and strong performance. In recent years, Hailing Pharma has successfully applied for a number of national invention patents and has obtained multiple clinical trial approvals. In addition, significant breakthroughs have been achieved in the fields of anti-infection and oncology.
3:28–4:06
Commercial network and historical market position
Historical sales-network and market-position statements presented by the original film.
Hailing Pharma owns over 30 sales and marketing offices, and its sales network covers more than 4,000 secondary and tertiary-level hospitals in 31 provinces, municipalities, and autonomous regions. The market share goes up year by year. According to data from MENET, under the former CFDA Southern Medicine Economic Research Institute, Hailing Pharma is ranked second in domestic antibiotic market. Two core products of Hailing Pharma, Ceftazidime for injection, and latamoxef sodium for injection, are listed second and fifth respectively in the domestic antibiotics market. Forging ahead more than a decade,
4:06–4:53
Service, reputation and historical recognition
The film describes service values, reputation and recognitions associated with its production period.
every Hailing Pharma staff put their dedication into their daily work and make great efforts to provide quality service to customers. With the comprehensive product brand image and excellent service, Hailing Pharma obtained great reputation in the China pharmaceutical market. It was honored as High and New Technology Enterprise, Science and Technology Innovation Oriented Enterprise, Top 10 Enterprises, Good Faith Demonstration Enterprise in Hainan Province, Top 100 Enterprises in China Pharmaceutical Industry, High Growth Chinese Top 50 of Pharmaceutical Industry, and Top 100 Enterprises of Hainan Province. Now, Hailing Pharma has successfully built up the high reputation and strong brand image in the China pharmaceutical industry.
4:53–5:59
Facilities, exports and international vision
A closing account of historical facility plans, export ambitions and the company's international outlook.
Over the past few years, Hailing Pharma invested RMB 200 million in the construction of aseptic, freeze-dried production facilities in Hainan under U.S. cGMP standards. It plans to build another first-class manufacturing plant, specializing in the production of anti-infection and oncology products. Hailing Pharma is now actively pursuing opportunities to export APIs and preparations with high added value to European and American pharmaceutical markets. In the near future, Hailing Pharma will go beyond China and become one of the leaders in global pharmaceutical industry. With a heart of craftsmen to care for the livelihood, with a spirit of benevolence to march all over the world, adhering to the tireless pursuit of caring people's health, Hailing Pharma will keep building a leading healthcare industrial platform in China and will dedicate itself to human health services. Hailing Pharma cares for life.